scholarly journals Combination of isocitrate dehydrogenase 1 ( IDH 1 ) mutation and podoplanin expression in brain tumors identifies patients at high or low risk of venous thromboembolism

2018 ◽  
Vol 16 (6) ◽  
pp. 1121-1127 ◽  
Author(s):  
P. Mir Seyed Nazari ◽  
J. Riedl ◽  
M. Preusser ◽  
F. Posch ◽  
J. Thaler ◽  
...  
Keyword(s):  
Venous Thromboembolism ◽  
Brain Tumors ◽  
Isocitrate Dehydrogenase ◽  
Low Risk ◽  
Isocitrate Dehydrogenase 1 ◽  
Podoplanin Expression

scholarly journals Podoplanin expression in primary brain tumors induces platelet aggregation and increases risk of venous thromboembolism

Blood ◽  
2017 ◽  
Vol 129 (13) ◽  
pp. 1831-1839 ◽  
Author(s):  
Julia Riedl ◽  
Matthias Preusser ◽  
Pegah Mir Seyed Nazari ◽  
Florian Posch ◽  
Simon Panzer ◽  
...  
Keyword(s):  
Brain Tumor ◽  
Venous Thromboembolism ◽  
Platelet Aggregation ◽  
High Risk ◽  
Brain Tumors ◽  
Tumor Patients ◽  
Primary Brain Tumors ◽  
Key Points ◽  
Podoplanin Expression ◽  
Very High

Key Points Brain tumor patients have a very high risk of VTE. Podoplanin expression by primary brain tumors induces platelet aggregation and is associated with hypercoagulability and a high risk of VTE.

scholarly journals Venous Thromboembolism in Brain Tumors: Risk Factors, Molecular Mechanisms, and Clinical Challenges

2019 ◽  
Vol 45 (04) ◽  
pp. 334-341 ◽  
Author(s):  
Julia Riedl ◽  
Cihan Ay
Keyword(s):  
Risk Factors ◽  
Venous Thromboembolism ◽  
Brain Tumors ◽  
Molecular Mechanisms ◽  
Tumor Biology ◽  
Idh1 Mutation ◽  
Point Of View ◽  
Isocitrate Dehydrogenase 1 ◽  
Primary Brain Tumors ◽  
Increased Risk

AbstractVenous thromboembolism (VTE) is a common complication in patients with primary brain tumors, with up to 20% of patients per year having a VTE event. Clinical risk factors for VTE include glioblastoma subtype, paresis, or surgery. Furthermore, specific factors playing a role in tumor biology were recently identified to predispose to prothrombotic risk. For instance, mutations in the isocitrate dehydrogenase 1 (IDH1) gene, which occurs in a subgroup of glioma, correlate with risk of VTE, with low incidence in patients with presence of an IDH1 mutation compared with those with IDH1 wild-type status. In addition, expression of the glycoprotein podoplanin on brain tumors was associated with both intratumoral thrombi and high risk of VTE. As podoplanin has the ability to activate platelets, a mechanistic role of podoplanin-mediated platelet activation in VTE development has been suggested. From a clinical point of view, the management of patients with primary brain tumors and VTE is challenging. Anticoagulation is required to treat patients; however, it is associated with increased risk of intracranial hemorrhage. This review focuses on describing the epidemiology, risk factors, and mechanisms of brain tumor-associated thrombosis and discusses clinical challenges in the prevention and treatment of VTE in patients with brain tumors.

Programmed Cell Death Ligand 1 and Venous Thromboembolism in Patients with Primary Brain Tumors

2019 ◽  
Author(s):  
P. Seyed Mir ◽  
A.-S. Berghoff ◽  
M. Preusser ◽  
G. Ricken ◽  
J. Riedl ◽  
...  
Keyword(s):  
Cell Death ◽  
Venous Thromboembolism ◽  
Programmed Cell Death ◽  
Brain Tumors ◽  
Primary Brain Tumors

Structural analysis of oncogenic mutation of isocitrate dehydrogenase 1

2016 ◽  
Vol 12 (7) ◽  
pp. 2276-2287 ◽  
Author(s):  
Vidya Rajendran
Keyword(s):  
Structural Analysis ◽  
Isocitrate Dehydrogenase ◽  
Isocitrate Dehydrogenase 1 ◽  
Oncogenic Mutation

Arginine to histidine mutation at position 132 (R132H) in isocitrate dehydrogenase 1 (IDH1) led to reduced affinity of the respective enzymes for isocitrate and increased affinity for α-ketoglutarate (AKG) and NADPH.

Sign in / Sign up

Export Citation Format

Share Document